UBS AM’s Atea Pharmaceuticals AVIR Stock Holding History

UBS AM’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8K	Hold	2,319	–	–	﹤0.01%	3255
2026 Q1	$12.5K	Buy	+2,319	New	+$10.7K	﹤0.01%	3261
2023 Q3	–	Sell	-90,068	Closed	-$302K	–	2598
2023 Q2	$302K	Hold	90,068	–	–	﹤0.01%	2474
2023 Q1	$302K	Hold	90,068	–	–	﹤0.01%	2474
2022 Q4	$433K	Buy	90,068 +2,620	+3%	+$13.3K	﹤0.01%	2232
2022 Q3	$498K	Sell	87,448 -14,138	-14%	-$108K	﹤0.01%	2347
2022 Q2	$721K	Buy	101,586 +85,437	+529%	+$583K	﹤0.01%	2133
2022 Q1	$117K	Hold	16,149	–	–	﹤0.01%	2729
2021 Q4	$144K	Buy	16,149 +3,523	+28%	+$54.9K	﹤0.01%	2795
2021 Q3	$443K	Buy	+12,626	New	+$350K	﹤0.01%	2542

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS AM's AVIR Position: Q2 2026 in Review

UBS AM held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 2,319 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

UBS AM first reported a position in AVIR in Q3 2021 and has held it in 10 quarters since. The position peaked at $721K in Q2 2022. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

UBS AM held 2,319 shares of Atea Pharmaceuticals worth $10.8K as of Q2 2026.
UBS AM left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3255 holding.
UBS AM first reported a position in Atea Pharmaceuticals in Q3 2021 and has held it in 10 quarters since.
UBS AM's Atea Pharmaceuticals position peaked at $721K in Q2 2022.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.